Nivolumab trials for Metastatic Melanoma

All Nivolumab trials · All Metastatic Melanoma trials

Phase breakdown

Recruiting trials studying Nivolumab for Metastatic Melanoma

• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 331 locations
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
  NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• Cryoablation+Ipilimumab+Nivolumab in Melanoma
  NCT05779423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
  NCT07422779 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
  NCT04697576 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
  NCT05655312 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 13 locations
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
  NCT05629546 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
  NCT07504796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Nivolumab for Metastatic Melanoma?

9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.